Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 8/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311974 | 1.00 | TRPA1 (0.43) | TRPA1PAX8GLAPTGDR2LMNA | |
| SCHEMBL6311968 | 1.00 | TRPA1 (0.43) | TRPA1PAX8GLAPTGDR2LMNA | |
| SCHEMBL7564357 | 0.85 | TRPA1 (0.53) | TRPA1PAX8GLALMNAMAPT | |
| SCHEMBL6310767 | 0.83 | GLA (0.45) | TRPA1GLAPTGDR2LMNAMAPT | |
| SCHEMBL6319715 | 0.83 | GLA (0.45) | TRPA1GLAPTGDR2LMNAMAPT | |
| SCHEMBL6319712 | 0.83 | GLA (0.45) | TRPA1GLAPTGDR2LMNAMAPT | |
| SCHEMBL6309688 | 0.81 | ALDH1A1 (0.49) | TRPA1GLAPTGDR2LMNAMAPT | |
| SCHEMBL6309694 | 0.81 | ALDH1A1 (0.49) | TRPA1GLAPTGDR2LMNAMAPT | |
| SCHEMBL5769625 | 0.75 | TACR1 (0.42) | PAX8 | |
| SCHEMBL5747031 | 0.75 | TACR1 (0.42) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153951-A1 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | KANOJIA RAMESH M (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-6809107-B1 | NEURODEGENERATIVE DISEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | TRPA1 94/4885PAX8 2522/4885GLA 4644/4885 |
| US-20050153951-A1 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | BDNF, NTRK2, NGF | TRPA1 448/4885PAX8 1111/4885GLA 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.